Latest news
CardiNor signs US distribution agreement with IBL-America for the CardiNor Research Use Only Secretoneurin ELISA test.
Press releases
2022
2021
CardiNor secures NOK12 million to commercialise first secretoneurin (SN) ELISA test
2018
2016
New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease
2015
CardiNor receives USD 0.75M to develop “missing link” CV risk test.
In the media
Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)
Scientific Nordic, 02.10.2015:
Unicard, 12.03.2015:
VG, 27.09.2015: